Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness
Barbara Barun, Tereza Gabelić, Ivan Adamec, Antonija Babić, Hrvoje Lalić, Drago Batinić, Magdalena Krbot Skorić, Mario Habek
Topics & Concepts
MedicineOcrelizumabMultiple sclerosisCoronavirus disease 2019 (COVID-19)PandemicDosing2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Intensive care medicineVirologyImmunologyPharmacologyInternal medicineInfectious disease (medical specialty)DiseaseRituximabOutbreakLymphomaMultiple Sclerosis Research StudiesSARS-CoV-2 and COVID-19 ResearchPeripheral Neuropathies and Disorders